If you’d told anyone a decade ago that a 150-year-old insulin maker from Indiana would join the $1 trillion club alongside Apple and Microsoft, they’d have laughed. Yet that’s exactly what Eli Lilly just did. On the back of its breakthrough weight-loss and diabetes drugs Mounjaro (tirzepatide) and Zepbound, Lilly has become the first pharma…